Zhejiang medicine "1 billion level" new drug is expected to go on the market in October

It is regarded as the most effective "the latest generation of quinolones" in the same kind of drugs by the industry The research and development progress and marketing schedule of nanofloxacin malate and its capsules have always been the most concern of Zhejiang Pharmaceutical (600216) investors At the extraordinary general meeting of shareholders on September 12, ye Weidong, Secretary of the board of directors of Zhejiang Pharmaceutical, said that ninofloxacin malate and its capsules obtained the production approval in June this year and obtained the new drug certificate as scheduled Then, around the marketing of the new drug, we carried out market development planning, raw and auxiliary materials procurement certification, drug packaging design and other related work According to the current plan, it is expected to go on sale in October In June 2012, Zhejiang Pharmaceutical signed the technology licensing and cooperation agreement with Taijing Biotechnology Co., Ltd and Taijing pharmaceutical R & D (Beijing) Co., Ltd., and obtained the patent use right and sales right in China The industry has predicted that according to the sales of similar products, nanofloxacin malate and its capsules are expected to become a "1 billion class" large variety of Zhejiang medicine, with an annual profit of about 500 million yuan Nanofloxacin malate and its capsules, known as "super anti bacterial drugs" in the industry, can be used as the first-line drug for community-acquired pneumonia In 2015, the global sales of quinolones of the same kind of drugs reached US $2.023 billion, and the sales of drugs in hospitals in major cities in the domestic market reached RMB 1.559 billion At present, quinolones, including moxifloxacin and levofloxacin, rank the top in the domestic market Among them, the best-known moxizaxing produced by Bayer company in Germany has a sales volume of about 1 billion yuan in China.